Literature DB >> 8158253

In the rat, endogenous nitric oxide modulates the response of the hypothalamic-pituitary-adrenal axis to interleukin-1 beta, vasopressin, and oxytocin.

C Rivier1, G H Shen.   

Abstract

Nitric oxide (NO) synthase (NOS), the enzyme responsible for NO formation, is found in hypothalamic neurons containing oxytocin (OT), vasopressin (VP), and to a lesser extent corticotropin-releasing factor (CRF). Because NO is reported to modulate endocrine activity, we have investigated the hypothesis that endogenous NO participates in ACTH released by various secretagogues in the rat. In the adult male rat, the intravenous injection of interleukin-1 beta (IL-1 beta; 0.2-0.3 micrograms/kg), VP (0.3-0.9 micrograms/kg), and OT (30 micrograms/kg) significantly increased plasma ACTH and corticosterone levels. Pretreatment with the L-form, but not the D-form, of N omega nitro-L-arginine-methylester (L-NAME; a specific inhibitor of NOS) markedly augmented the effects of these secretagogues whether it was injected acutely or over a 4 d period. Blockade of NOS activity also caused significant (P < 0.01) extensions of the duration of action of IL-1 beta, VP, and OT. In contrast, L-NAME did not significantly alter the stimulatory action of peripherally injected CRF, or centrally administered IL-1 beta. Administration of L-arginine, but not D-arginine (100 mg/kg), used as a substrate for basal NO synthesis and which did not by itself alter the activity of the hypothalamic-pituitary-adrenal (HPA) axis, blunted IL-1-induced ACTH secretion, and reversed the interaction between L-NAME and IL-1 beta. The stimulatory action of endotoxin, a lipopolysaccharide that releases endogenous cytokines, was also augmented by inhibition of NO formation.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8158253      PMCID: PMC6577127     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  13 in total

Review 1.  NO as a signalling molecule in the nervous system.

Authors:  Juan V Esplugues
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Nitric oxide regulates NMDA-driven GABAergic inputs to type I neurones of the rat paraventricular nucleus.

Authors:  J S Bains; A V Ferguson
Journal:  J Physiol       Date:  1997-03-15       Impact factor: 5.182

3.  Deletion of the ventral noradrenergic bundle obliterates the early ACTH response after systemic LPS, independently from the plasma IL-1β surge.

Authors:  L Givalois; S Gaillet; M Mekaouche; C Ixart; A F Bristow; P Siaud; A Szafarczyk; F Malaval; I Assenmacher; G Barbanel
Journal:  Endocrine       Date:  1995-07       Impact factor: 3.633

4.  Estrogen downregulates neuronal nitric oxide synthase in rat anterior pituitary cells and GH3 tumors.

Authors:  X Qian; L Jin; R V Lloyd
Journal:  Endocrine       Date:  1999-10       Impact factor: 3.633

5.  An initial, three-day-long treatment with alcohol induces a long-lasting phenomenon of selective tolerance in the activity of the rat hypothalamic-pituitary-adrenal axis.

Authors:  S Lee; C Rivier
Journal:  J Neurosci       Date:  1997-11-15       Impact factor: 6.167

6.  Chronic inhibition of nitric oxide synthase augments the ACTH response to exercise.

Authors:  Ryan Jankord; Richard M McAllister; Venkataseshu K Ganjam; M Harold Laughlin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-14       Impact factor: 3.619

7.  Selective inhibitors of nitric oxide synthase (NOS) implicate a constitutive isoform of NOS in the regulation of interleukin-1-induced ACTH secretion in rats.

Authors:  A V Turnbull; C Rivier
Journal:  Endocrine       Date:  1996-10       Impact factor: 3.633

Review 8.  Role of various neurotransmitters in mediating the long-term endocrine consequences of prenatal alcohol exposure.

Authors:  Soon Lee; Irene Choi; Sang Kang; Catherine Rivier
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor.

Authors:  J Gulyas; C Rivier; M Perrin; S C Koerber; S Sutton; A Corrigan; S L Lahrichi; A G Craig; W Vale; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-07       Impact factor: 11.205

10.  Inhibition of tumor necrosis factor-alpha action within the CNS markedly reduces the plasma adrenocorticotropin response to peripheral local inflammation in rats.

Authors:  A V Turnbull; F J Pitossi; J J Lebrun; S Lee; J C Meltzer; D M Nance; A del Rey; H O Besedovsky; C Rivier
Journal:  J Neurosci       Date:  1997-05-01       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.